Spironolactone Tablet
Product Images NDC 71610-970

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 71610-970). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (71610 0970 45)

Label (71610 0970 45)
SPIRONOLACTONE 25 mg oral tablets label showing 45 tablets per bottle. Includes storage instructions, manufacturer BioPharm Inc., Philadelphia, PA, and repackager Aphena Pharma, Cookeville, TN. Displays NDC 71610-970-45 and indicates prescription use only.*
FDA Label Image

Aphena (Aphena)

Aphena (Aphena)
FDA Label Image

Structure (Spironolactone 01)

Structure (Spironolactone 01)
Chemical structure of spironolactone, a human prescription drug. The diagram shows the molecular composition with characteristic rings and functional groups including ketones and a sulfur-containing moiety.*
FDA Label Image

Figure 1 (Spironolactone 02)

Figure 1 (Spironolactone 02)
A Kaplan-Meier survival curve chart showing probability over time in months up to 48 months. The chart compares two groups labeled Spironolactone (n=822) and Placebo (n=841) with a log-rank p-value of less than 0.001, indicating a statistically significant difference in survival distributions.*
FDA Label Image

Figure 2 (Spironolactone 03)

Figure 2 (Spironolactone 03)
A forest plot chart showing hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups in a study analyzing spironolactone versus placebo. The subgroups include age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use, with each subgroup’s sample size noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.